| Literature DB >> 24667815 |
Paola Cristina Resende1, Fernando C Motta1, Maria de Lourdes A Oliveira1, Tatiana S Gregianini2, Sandra B Fernandes3, Ana Luisa F Cury4, Maria do Carmo D Rosa5, Thiago Moreno L Souza1, Marilda M Siqueira1.
Abstract
The D222G substitution in the hemagglutinin (HA) gene of the pandemic influenza A(H1N1)pdm09 virus has been identified as a potential virulence marker, because this change allows for virus invasion deeper into the respiratory tract. In this study, we analyzed D, G and N polymorphisms at residue 222 by pyrosequencing (PSQ). We initially analyzed 401 samples from Brazilian patients. These were categorized with respect to clinical conditions due to influenza infection (mild, serious or fatal) and sub-stratified by risky factors. The frequency of mixed population of virus, with more than one polymorphism at residue 222, was significantly higher in serious (10.6%) and fatal (46.7%) influenza cases, whereas those who showed mild influenza infections were all infected by D222 wild-type. Mixtures of quasi-species showed a significant association of mortality, especially for those with risk factors, in special pregnant women. These results not only reinforce the association between D222G substitution and influenza A(H1N1)pdm09-associated morbidity and mortality, but also add the perspective that a worse clinical prognosis is most likely correlated with mixtures of quasi-species at this HA residue. Therefore, quasi-species may have a critical and underestimated role in influenza-related clinical outcomes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24667815 PMCID: PMC3965456 DOI: 10.1371/journal.pone.0092789
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sociodemographic, clinical and epidemiological characteristics according to Influenza A (H1N1)pdm09 HA 222 polymorphisms.
| Variables | N/Total (%) | Polymorphisms at 222 HA residue | p value* | ||
| D (WT) | G | Mixed1 | |||
|
| < 0.001 | ||||
| Pandemic period | 301/401 (75.1) | 232/301 (77.1) | 8/301 (2.2) | 61/301 (15.2) | |
| Post pandemic period | 100/401 (24.9) | 99/100 (99.0) | 1/100 (1.0) | 0/100 (0.0) | |
|
| < 0.001 | ||||
| South | 227/401 (56.6) | 197/227 (86.8) | 5/227 (2.2) | 25/227 (11.0) | |
| Southeast | 150/401 (37.4) | 120/150 (80.0) | 4/150 (2.7) | 26/150 (17.3) | |
| Northeast | 21/401 (5.3) | 11/21 (52.4) | 0/21 (0.0) | 10/21 (47.6) | |
| North | 3/401 (0.7) | 3/3 (100.0) | 0/3 (0.0) | 0/3 (0.0) | |
|
| 0.605 | ||||
| Female | 221/401 (55.1) | 179/221 (81.0) | 6/221 (2.7) | 36/221 (16.3) | |
| Male | 180/401 (44.9) | 152/180 (84.4) | 3/180 (1.7) | 25/180 (13.9) | |
|
| 0.093 | ||||
| Upper respiratory tract | 392/401 (97.8) | 326/392 (83.2) | 9/392 (14.5) | 57/392 (14.5) | |
| Lower respiratory tract | 9/401 (2.2) | 5/9 (55.6) | 4/9 (44.4) | 0/9 (0.0) | |
|
| < 0.001 | ||||
| Mild | 52/305 (17.0) | 52/52 (100.0) | 0/52 (0.0) | 0/52 (0.0) | |
| Serious | 161/305 (52.8) | 140/161 (87.0) | 4/161 (2.5) | 17/161 (10.6) | |
| Fatal | 92/305 (30.2) | 44/92 (47.8) | 5/92 (5.4) | 43/92 (46.7) | |
WT, wild type D222; Pandemic period (EW 17/2009 to 9/2010); Post pandemic period (EW 22/2011 to 35/2011); Serious cases were defined as those who presented SARI or pneumonia and/or demanded hospitalization; EW, epidemiological week. 1G222 or mixed populations - regarded as the polymorphisms G/N; G/D; N/D or N/G/D at the 222 HA residue. *Associations were assessed by Pearson Chi-square tests and p value was considered significant when <0.05.
Distribution of polymorphisms at 222 HA residue in Influenza A(H1N1)pdm09 fatal cases, according to comorbidity or underlying disease.
| Risk factors | N fatal/ Total | Polymorphisms at 222 HA residue |
| ||||||
| D | G | G/D | N/D | N/G | N/G/D | G or Mixed population | |||
| Any risk factor | 35/154 | 20/125 | 3/6 | 1/9 | 1/2 | 3/3 | 7/9 | 15/29 | < 0.001 |
| Pregnancy | 15/47 | 7/34 | 1/2 | 3/4 | 0/0 | 3/3 | 1/4 | 8/13 | 0.013 |
| Chronic cardiovascular disorder | 11/33 | 7/26 | 0/0 | 0/3 | 1/1 | 0/0 | 3/3 | 4/7 | 0.186 |
| Chronic pulmonary disorder | 2/24 | 1/22 | 0/1 | 0/0 | 0/0 | 0/0 | 1/1 | 1/2 | 0.163 |
| Metabolic disorder | 11/27 | 6/19 | 1/2 | 0/1 | 0/1 | 1/1 | 3/3 | 5/8 | 0.206 |
| Imunodepression | 5/33 | 4/29 | 0/0 | 1/3 | 0/0 | 0/0 | 0/1 | 1/4 | 0.500 |
| Tabagism | 5/20 | 4/16 | 1/2 | 0/1 | 0/0 | 0/0 | 0/1 | 1/4 | 1.00 |
| Chronic renal disorder | 3/7 | 2/6 | 0/0 | 1/1 | 0/0 | 0/0 | 0/0 | 1/1 | 0.429 |
* Associations were assessed by Pearson Chi-square tests and p value was considered significant when <0.05.